Please try another search
By Shreyashi Sanyal and Anisha Sircar
(Reuters) -European shares rose on Friday after drugmakers rebounded following a slump in the previous session, and Flutter fanned a rally in the travel and leisure sector after an upbeat earnings forecast.
Shares in GSK, Sanofi (NASDAQ:SNY) and Haleon rose between 0.8% and 3.6% after the drugmakers said that nothing material had changed regarding U.S. litigation focused on heartburn drug Zantac.
The stocks had fallen sharply this week on concerns over potential cancer-causing impurities that prompted the drug's withdrawal from markets.
The European healthcare sector gained 0.2%, with the STOXX 600 index also rising 0.2%.
"We raise (European) pharma from marketweight to overweight, as our macro projections imply scope for 10%+ outperformance by the first quarter next year after the sharp recent pull-back," said Sebastian Raedler and Thomas Pearce, investment strategists at Bank of America (NYSE:BAC).
But any rallies in the STOXX 600 are not likely to last, they added. "The main prerequisite for a sustained rally is a trough in the macro cycle and renewed acceleration in growth momentum, but growth headwinds remain considerable."
Euro area PMI is likely to be weaker due to tightening credit, and low Russian gas deliveries raise the risk of winter rationing, which could tip the region into recession, the strategists added.
A European bank agreed to process a payment for the transit of Russian oil through Ukraine, sources said, removing the cause of a stoppage of oil supplies to central Europe last week.
Meanwhile, travel & leisure stocks jumped 3.9% to more than two month highs, leading sectoral gains.
Flutter surged 14.4% to the top of the travel index, as it saw no sign of cash-strapped customers betting less and gave another positive update on its rapidly growing U.S. business.
Irish stocks added 2.7%, boosted by Flutter.
The STOXX 600 index, up for a third straight day, notched weekly gains of 1.2% as positive earnings and a softer-than-expected U.S. inflation reading calmed nerves around aggressive rate hikes by the Federal Reserve, though concerns remain over policymakers' path.
European shares have fallen 9.6% so far this year compared with a nearly 11% decline for Wall Street's S&P 500 index, which was largely dragged down by drops in big growth stocks in the first half of the year.
London stocks gained 0.5% after data showed Britain's economy contracted by less than feared in the second quarter. (L)
Roche rose 1.6% after the drugmaker received approval from the U.S. Food and Drugs Administration for its Xofluza drug to treat influenza in children aged five years and older.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.